Skip to main content

Candel Therapeutics, Inc.

CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001841387

In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Candel Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
4 filings
3 insiders, $3.55M in total
Insiders trading
3
Net value
−$3.55M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Candel Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Candel Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Tak Paul PeterChief Executive Officer113,321Sep 11, 20262
Zimmermann MartineDirector–Sep 10, 20261
Tyagarajan SeshuChief Technology Officer76,865Aug 19, 20263
Sims Mark E.Chief Commercial Officer–Jul 8, 20261
Barone FrancescaChief Scientific Officer77,362Jul 1, 20262
Manning Paul BDirector2,763,527IndirectJul 1, 20264
Papa Joseph CDirector64,239IndirectJul 1, 20263
Loggia NicolettaDirector2,141Jul 1, 20263
Benz Edward J. JRDirector–Jun 24, 20261
Gaeta ReneeDirector–Jun 24, 20261
Nguyen DiemDirector10,000Jun 24, 20261
Nabel Gary J.Director5,353Jun 24, 20261
Martell ChristopherDirector111,349IndirectJun 24, 20261
Radhakrishnan MahaDirector–Jun 24, 20261
Nichols William GarrettChief Medical Officer52,493Jan 28, 20261
Schoch CharlesChief Financial Officer43,391Jan 28, 20261
Aguilar Laura K.10% Owner162,929Feb 25, 20250
Aguilar-Cordova Estuardo10% Owner162,929Feb 25, 20250
Amello JasonChief Financial Officer202,009Nov 30, 20230
Stewart Susan B.Chief Regulatory Officer–Apr 12, 20220
Canepa John JChief Financial Officer10,125Mar 1, 20220
Caffo NathanChief Business Officer6,000Aug 2, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 11, 2026 (view filing)6:12 PM ETSep 10-111 dayTak Paul PeterChief Executive OfficerSSale−280.2K$11.28−$3.16M−71.2%113.3K after2 lots10b5-1
Aug 19, 2026 (view filing)4:30 PM ETAug 172 daysTyagarajan SeshuChief Technology OfficerSSale−7.00K$12.00−$84.0K−8.3%76.9K after10b5-1
Jul 1, 2026 (view filing)4:22 PM ETJun 292 daysBarone FrancescaChief Scientific OfficerSSale−23.4K$10.06−$235.8K−23.3%77.4K after10b5-1
Jul 1, 2026 (view filing)4:22 PM ETJun 292 daysTyagarajan SeshuChief Technology OfficerSSale−7.00K$10.02−$70.2K−7.7%83.9K after10b5-1
Feb 26, 2026 (view filing)Feb 233 daysLateManning Paul BDirectorPPurchase+550.5K$5.45+$3.00M+24.9%2.76M after
Jul 30, 2025 (view filing)Jul 282 daysNichols William GarrettChief Medical OfficerSSale−937$6.98−$6.54K−1.8%52.5K after10b5-1
Jul 2, 2025 (view filing)Jun 302 daysNichols William GarrettChief Medical OfficerSSale−781$5.04−$3.94K−1.5%52.5K after10b5-1
Mar 20, 2025 (view filing)Mar 182 daysNichols William GarrettChief Medical OfficerSSale−45.3K$8.76−$397.0K−46.3%52.5K after10b5-1
Mar 20, 2025 (view filing)Mar 182 daysBarone FrancescaChief Scientific OfficerSSale−32.1K$8.76−$281.6K−25.0%96.5K after10b5-1
Mar 20, 2025 (view filing)Mar 18-192 daysTak Paul PeterChief Executive OfficerSSale−26.2K$8.77−$229.6K−10.4%225.7K after2 lots10b5-1
Mar 20, 2025 (view filing)Mar 173 daysTyagarajan SeshuChief Technology OfficerSSale−31.3K$8.82−$275.9K−26.8%85.5K afterAmended10b5-1
Mar 19, 2025 (view filing)Mar 172 daysSchoch CharlesSee RemarksSSale−5.00K$8.83−$44.1K−11.6%38.0K after10b5-1
Jan 17, 2025 (view filing)Jan 152 daysTyagarajan SeshuChief Technology OfficerSSale−14.3K$7.23−$103.5K−12.9%96.8K after
Jan 17, 2025 (view filing)Jan 152 daysBarone FrancescaChief Scientific OfficerSSale−13.5K$7.23−$97.9K−10.9%110.7K after
Jan 17, 2025 (view filing)Jan 152 daysSchoch CharlesSee RemarksSSale−9.51K$7.23−$68.8K−18.1%43.0K after
Jan 17, 2025 (view filing)Jan 152 daysTak Paul PeterChief Executive OfficerSSale−21.7K$7.23−$156.9K−7.9%251.9K after
Jan 17, 2025 (view filing)Jan 152 daysNichols William GarrettChief Medical OfficerSSale−10.4K$7.23−$75.4K−11.6%79.3K after
Jan 10, 2025 (view filing)Jan 82 daysBarone FrancescaChief Scientific OfficerSSale−13.7K$8.22−$112.4K−9.9%124.2K after
Jan 10, 2025 (view filing)Jan 82 daysSchoch CharlesSee RemarksSSale−9.97K$8.22−$82.0K−15.9%52.5K after
Jan 10, 2025 (view filing)Jan 82 daysTak Paul PeterChief Executive OfficerSSale−21.2K$8.22−$174.0K−7.2%273.6K after
Jan 10, 2025 (view filing)Jan 82 daysTyagarajan SeshuChief Technology OfficerSSale−14.5K$8.22−$119.6K−11.6%111.1K after
Jan 10, 2025 (view filing)Jan 82 daysNichols William GarrettChief Medical OfficerSSale−10.8K$8.22−$88.8K−10.7%89.7K after
Dec 18, 2024 (view filing)Dec 162 daysManning Paul BDirectorPPurchase+1.25M$6.00+$7.50M+2,325.5%1.30M after2 lots
Dec 3, 2024 (view filing)Nov 294 daysTyagarajan SeshuChief Technology OfficerSSale−20.4K$4.56−$93.0K−14.0%125.7K after
Dec 3, 2024 (view filing)Nov 294 daysTak Paul PeterChief Executive OfficerSSale−48.8K$4.56−$222.7K−14.2%294.8K after
Dec 3, 2024 (view filing)Nov 294 daysNichols William GarrettChief Medical OfficerSSale−13.9K$4.56−$63.5K−12.2%100.5K after
Dec 3, 2024 (view filing)Nov 294 daysBarone FrancescaChief Scientific OfficerSSale−22.1K$4.56−$100.7K−13.8%137.9K after
Oct 15, 2024 (view filing)5:59 PM ETOct 11-154 daysAguilar Laura K. and 1 other10% OwnerSSaleCADL−40.4K$6.03−$243.8K−4.2%919.5K after3 lots
Oct 3, 2024 (view filing)6:19 PM ETOct 12 daysAguilar Laura K. and 1 other10% OwnerSSaleCADL+6.21K$7.01+$43.6K+0.6%988.7K after
Oct 3, 2024 (view filing)6:19 PM ETOct 2-31 dayAguilar Laura K. and 1 other10% OwnerSSaleCADL−28.8K$6.92−$199.1K−2.9%959.9K after2 lots
Jul 19, 2024 (view filing)Jul 172 daysTyagarajan SeshuChief Technology OfficerSSale−14.9K$6.47−$96.1K−9.2%146.0K after
Jul 19, 2024 (view filing)Jul 172 daysTak Paul PeterChief Executive OfficerSSale−22.5K$6.47−$145.8K−6.4%330.7K after
Jul 19, 2024 (view filing)Jul 172 daysSchoch CharlesSee RemarksSSale−9.88K$6.47−$63.9K−13.7%62.5K after
Jul 19, 2024 (view filing)Jul 172 daysNichols William GarrettChief Medical OfficerSSale−10.9K$6.47−$70.4K−8.7%114.5K after
Jul 19, 2024 (view filing)Jul 172 daysBarone FrancescaChief Scientific OfficerSSale−14.1K$6.47−$90.9K−8.1%160.0K after
Jul 15, 2024 (view filing)Jul 114 daysTyagarajan SeshuChief Technology OfficerSSale−13.3K$5.97−$79.6K−7.7%160.9K after
Jul 15, 2024 (view filing)Jul 114 daysTak Paul PeterChief Executive OfficerSSale−20.3K$5.97−$121.1K−5.4%353.3K after
Jul 15, 2024 (view filing)Jul 114 daysSchoch CharlesSee RemarksSSale−8.90K$5.97−$53.1K−10.9%72.4K after
Jul 15, 2024 (view filing)Jul 114 daysNichols William GarrettChief Medical OfficerSSale−9.77K$5.97−$58.3K−7.2%125.4K after
Jul 15, 2024 (view filing)Jul 114 daysBarone FrancescaChief Scientific OfficerSSale−12.6K$5.97−$75.5K−6.8%174.0K after
Feb 17, 2023 (view filing)Dec 8-9, 202271 daysMartell ChristopherDirectorPPurchase+27.0K$1.89+$51.1K+21.6%152.0K afterAmended2 lots
Dec 12, 2022 (view filing)Dec 84 daysBarone FrancescaChief Scientific OfficerPPurchase+1.24K$1.61+$1.99K+82.5%2.74K after
Dec 12, 2022 (view filing)Dec 8-94 daysPapa Joseph CDirectorPPurchase+38.0K$1.92+$73.1KNew position38.0K after2 lots
Dec 12, 2022 (view filing)Dec 8-94 daysTyagarajan SeshuChief Technology OfficerPPurchase+13.4K$1.88+$25.1KNew position13.4K after2 lots
Dec 12, 2022 (view filing)Dec 8-94 daysAmello JasonChief Financial OfficerPPurchase+5.57K$1.80+$10.0KNew position5.57K after2 lots
Dec 12, 2022 (view filing)Dec 8-94 daysTak Paul PeterChief Executive OfficerPPurchase+16.0K$1.88+$30.0K+63.9%41.0K after2 lots
Aug 4, 2021 (view filing)Jul 296 daysManning Paul BDirector, 10% OwnerPPurchase+1.63M$8.00+$13.0M+2,901.8%1.68M afterAmended
Aug 2, 2021 (view filing)Jul 294 daysMartell ChristopherDirectorPPurchase+125.0K$8.00+$1.00MNew position125.0K after
Aug 2, 2021 (view filing)Jul 294 daysNguyen DiemDirectorPPurchase+10.0K$8.00+$80.0KNew position10.0K after
Aug 2, 2021 (view filing)Jul 294 daysTak Paul PeterChief Executive OfficerPPurchase+25.0K$8.00+$200.0KNew position25.0K after